Importance of biomarker testing in diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL)



In this document, Dr Cathy Burton, Consultant Haematologist, Leeds Teaching Hospitals NHS Trust covers:
 

  • The diagnostic tools for biomarker testing in DLBCL and MCL
  • How biomarkers influence diagnosis and treatment decisions
  • How biomarkers affect prognosis

For further information on Demystifying the complexity of lymphoma classification please click here.

 

 

Only to be shared with relevant UK haematology healthcare professionals.

CPD® Accreditation

To support your continued professional development the resources hosted in the Resources hub have been certified for CPD® accreditation by the CPD® Certification Service.

Please complete the Request CPD® Certificate form to request a CPD® accredited certificate.